Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Animation immunotherapy with IMP321 - MedicalGraphics
(PDF) MART-1 peptide vaccination plus IMP321 (LAG-3Ig fusion protein ...
A Phase I Study of IMP321 and Gemcitabine as the Front-line Therapy in ...
IMP321 increases the numbers of monocytes, NK and activated CD8 T cells ...
(PDF) IMP321 (sLAG-3), an immunopotentiator for T cell responses ...
IMP321 Industrial Pressure Transmitter
ICS Schneider IMP321 Industrial Pressure Transmitter 116-4002-1-2-100 ...
Table 1 from Journal of Immune Based Therapies and Vaccines Imp321 ...
USA Patent Granted for IMP321 Cancer Treatment | PDF | Pharmacology ...
IMP321 Enhancing Anti-PD-1 in Melanoma Clinical Trial: Get alerts for ...
Slide 7
eftilagimod alpha-药品详情-NextPharma®数据库-ByDrug-医药魔方数据库
LOGO
Slide 15
LAG-3靶点机制和研究进展 - 知乎
Slide 23
知其奥 助其药 | 药明奥测已成功开发LAG-3抗体RUO试剂盒 定位准确、灵敏度高_中华网
Slide 11
Slide 10
Slide 13
Slide 14
Slide 5
Slide 12
IMP-321 | TargetMol
Figure 2 from A Soluble Form of Lymphocyte Activation Gene-3 (IMP321 ...
Eftilagimod alfa (IMP321) | MHC II类激动剂 | MCE
Slide 20
深度分析 | Immutep：小而有爆发潜力的LAG-3靶点研发公司 作者：蹊之 微信公众号：蹊之美股生物医药/CaesarBiotech ...
AIPAC: A Phase Iib Study of Eftilagimod Alpha (Imp321 or Lag-3Ig) Added ...
Combination of paclitaxel and a LAG-3 fusion protein (eftilagimod alpha ...
LAG-3单抗是什么？_钟润波_主任医师_爱问健康
LAG-3与PD-1进军免疫耐药，联手后逐渐摆脱LAG-3单药低谷|黑色素瘤|转移性|免疫|药物|-健康界
Prima BioMed has released new clinical data from its TACTI-mel Phase I ...
Illustrations mode of action cancer drug - MedicalGraphics
LAG-3融合蛋白Eftilagimod alpha联合帕博利珠单抗一线治疗肺癌-印塔健康官网
#insight003 #imp321 #eftilagimod_alpha #lag #clinicalresearch #oncology ...
Animation cancer immunotherapy - MedicalGraphics
CD Antigens - Proteins
Immutep公司LAG-3融合蛋白获FDA批准第二个IND 近日（2020年3月9日）， Immutep Limited 宣布美国食品和药物 ...
Figure 1 from A Soluble Form of Lymphocyte Activation Gene-3 (IMP321 ...
LAG-3+PD-1取得OS突破，Immutep股价大涨65% 2023年5月17日， Immutep 公布了其LAG-3融合蛋白 ...
Prima BioMed — Update 15 February 2017 - Edison Group
Figure 1 from A Phase I Pharmacokinetic and Biological Correlative ...
A phase I, single-institution, open-label, dose escalation trial with ...
FDA批准首款LAG-3抗体疗法，这类全新的癌症免疫疗法潜力多大？_腾讯新闻
Fibroblast growth factor receptor 3 (FGFR3), peroxisome proliferator ...
LAG-3分子结构的新见解 - 知乎
First-line chemoimmunotherapy in metastatic breast carcinoma ...
Figure 5 from A Soluble Form of Lymphocyte Activation Gene-3 (IMP321 ...
LAG-3 as a Potent Target for Novel Anticancer Therapies of a Wide Range ...
(PDF) First-line chemoimmunotherapy in metastatic breast carcinoma ...
Eftilagimod alfa獲FDA孤兒藥資格用於軟組織肉瘤治療 | Heal Oncology Center | Clinical ...
Vaccination with LAG-3Ig (IMP321) and peptides induces specific CD4 and ...
LAG-3疗法获FDA快速通道资格，联合K药一线治疗NSCLC医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
Nature：第三个免疫检查点抑制剂靶点Lag-3 - 平头哥
WO2017037203A1 - Anti-LAG-3 Antibodies - Google Patents
LAG-3靶向分子的临床开发研究进展 - 知乎
LAG-3：最新的独特激活机制研究
KR102453537B1 - 결합 검정 - Google Patents
头颈部肿瘤成为后PD-1时代潜力靶点的突破口？_efti_治疗_一线
最全！免疫检查点图文详解 - 知乎
Prima BioMed — Update 27 July 2016 - Edison Group
Lymphocyte-activation gene 3 (LAG-3) | ACROBiosystems
【产品推介】LAG-3靶点细胞筛选模型-南京科佰生物科技有限公司
靶向LAG-3免疫治疗的研究现状|抑制性|氨基酸|研究|细胞|-健康界
Prima BioMed — Update 1 August 2016 - Edison Group
Eftilagimod alfa| CAS NO:1800476-36-1| GlpBio
默克PD-L1/TGF-β将开展联合LAG-3疗法临床研究医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
Pelco - IMP321-1RS
WO2014140180A1 - Anti-lag-3 binding proteins - Google Patents
Prima BioMed — Initial LAG-3 combo data presented - Edison Group
FORM 20-F
An APC activator IMP 321 or LAG3 Ig
【靶点Talk】LAG-3，下一个风口？_仪器信息网社区
ISRE-Luc/NFκB-SEAP/THP-1_药靶模型_南京科佰生物科技有限公司
CN112638942A - 抗pd-l1抗体的给药方案及其用途 - Google Patents
